EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID‐19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV‐1 IM)

Stephen J Balevic iD, Daniel Gonzalez iD, P Brian Smith, William G Powderly, Andreas Schmid, Ashley Kang, Matthew W McCarthy, Linda K Shaw, Christopher J Lindsell, Sam Bozzette, Richard M W Hoetelmans, Christoph P Hornik und 2 weitere

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70057 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Stephen J Balevic und 13 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, NC, USA. Hauptthemen laut MEDLINE: Infliximab, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NICHD NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infliximab may play an important role in reducing mortality in severe COVID‐19, though optimal dosing is unknown. This secondary analysis of the ACTIV‐1 IM trial characterized infliximab pharmacokinetics and outcomes in patients hospitalized with severe COVID‐19. ACTIV‐1 IM included patients admitted with COVID‐19 pneumonia who received infliximab in addition to routine care. Infliximab was administered as a single 5‐mg/kg intravenous dose. The primary exposure variable was predicted infliximab concentrations over 28 days (AUC 0‐28 ). Logistic regression modeling was used to relate AUC 0‐28 to the primary outcome of 28‐day mortality, adjusted for age. The relationship between AUC 0‐28 and the secondary outcome of time to recovery was evaluated using a Fine–Gray model, adjusted for age, with death as a competing risk. AUC 0‐28 was higher in patients who did not die versus those who died, with a median (range) of 20,681 mg h/L (8379‐60,322) versus 17,392 (9543‐43,145), P < .001. A 5000‐unit increase in AUC 0‐28 was associated with decreased mortality (OR 0.62, 95% CI 0.43‐0.88, P = .008) and decreased composite safety events (OR 0.57, 95% CI 0.45‐0.71, P < .001). Higher AUC 0‐28 was associated with a greater probability of recovery; an AUC 0‐28 ≤ 17,400 mg h/L was associated with a 3.45‐fold higher (95% CI 2.23‐5.34) probability of recovery at Day 28, as was an AUC 0‐28 >17,400 mg h/L, albeit at a lower rate (1.18‐fold higher [95% CI 1.07‐1.32]), P < .002 for both. Overall, 113/390 (29.0%) patients did not achieve an optimal predicted infliximab AUC 0‐28 of at least 17,400 mg h/L, particularly those

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabCOVID-19 Drug TreatmentHumansMaleFemaleMiddle AgedAgedHospitalizationCOVID-19Area Under CurveSARS-CoV-2Dose-Response Relationship, DrugAdultTreatment Outcome

Stichwörter der Autor:innen

COVID‐19infliximabpharmacokinetics

Substanzen

Infliximab

Autor:innen und Institutionen

  • Duke Clinical Research Institute, Durham, NC, USA.
  • Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
  • Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Department of Medicine, Washington University St. Louis, St. Louis, MO, USA.
  • Deptartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
  • Hackensack University Medical Center, Hackensack, NJ, USA.

ORCID-Profile: Stephen J Balevic, Daniel Gonzalez

Förderung

  • NIAMS NIH HHS
  • NICHD NIH HHS
  • NCATS NIH HHS
  • NIAAA NIH HHS

Zitieren

APA

Balevic, S. J., Gonzalez, D., Smith, P. B., Powderly, W. G., Schmid, A., Kang, A., McCarthy, M. W., Shaw, L. K., Lindsell, C. J., Bozzette, S., Hoetelmans, R. M. W., Hornik, C. P., Benjamin, D. K., & ACTIV‐1 IM Study Group Members (2025). Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID‐19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV‐1 IM). The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70057

Vancouver

Balevic SJ, Gonzalez D, Smith PB, Powderly WG, Schmid A, Kang A, et al. Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID‐19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV‐1 IM). The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70057

BibTeX
@article{Balevic2025,
  author = {Balevic, Stephen J and Gonzalez, Daniel and Smith, P Brian and Powderly, William G and Schmid, Andreas and Kang, Ashley and McCarthy, Matthew W and Shaw, Linda K and Lindsell, Christopher J and Bozzette, Sam and Hoetelmans, Richard M W and Hornik, Christoph P and Benjamin, Daniel K and ACTIV‐1 IM Study Group Members, ACTIV‐1 IM Study Group Members},
  title = {Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID‐19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV‐1 IM)},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70057}
}
Kostenlos starten →